- Home
- PROK vs RCS Comparison
PROK vs RCS Comparison
Compare PROK & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- RCS
- Stock Information
- Founded
- PROK 2015
- RCS 1994
- Country
- PROK United States
- RCS United States
- Employees
- PROK N/A
- RCS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- RCS Investment Managers
- Sector
- PROK Health Care
- RCS Finance
- Exchange
- PROK Nasdaq
- RCS Nasdaq
- Market Cap
- PROK 417.1M
- RCS 358.4M
- IPO Year
- PROK N/A
- RCS N/A
- Fundamental
- Price
- PROK $2.97
- RCS $7.32
- Analyst Decision
- PROK Strong Buy
- RCS
- Analyst Count
- PROK 4
- RCS 0
- Target Price
- PROK $6.25
- RCS N/A
- AVG Volume (30 Days)
- PROK 2.1M
- RCS 141.1K
- Earning Date
- PROK 11-11-2025
- RCS 01-01-0001
- Dividend Yield
- PROK N/A
- RCS 10.12%
- EPS Growth
- PROK N/A
- RCS N/A
- EPS
- PROK N/A
- RCS N/A
- Revenue
- PROK $527,000.00
- RCS N/A
- Revenue This Year
- PROK $427.89
- RCS N/A
- Revenue Next Year
- PROK N/A
- RCS N/A
- P/E Ratio
- PROK N/A
- RCS N/A
- Revenue Growth
- PROK N/A
- RCS N/A
- 52 Week Low
- PROK $0.46
- RCS $4.51
- 52 Week High
- PROK $7.13
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- PROK 55.05
- RCS 43.42
- Support Level
- PROK $2.80
- RCS $7.53
- Resistance Level
- PROK $3.28
- RCS $7.78
- Average True Range (ATR)
- PROK 0.27
- RCS 0.22
- MACD
- PROK 0.01
- RCS -0.07
- Stochastic Oscillator
- PROK 57.52
- RCS 25.58
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.